Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: A model of 'systemic steatosis'

Ashok Balasubramanyam, Rajagopal V. Sekhar, Farook Jahoor, Peter H. Jones, Henry J. Pownall

Research output: Contribution to journalReview articlepeer-review

65 Scopus citations


Purpose of review: This review addresses a syndrome of dyslipidemia and lipodystrophy that has emerged in HIV-infected patients receiving highly active antiretroviral therapy (HAART). The term 'HIV/HAART associated dyslipidemic lipodystrophy (HADL)' describes this syndrome. Although HAART increases patient survival rates, their increased longevity and dyslipidemias place them at risk for cardiovascular disease. Identification of rationally based therapies requires an understanding of the mechanistic basis of HADL. Recent findings: A case definition for HIV lipodystrophy, based on age, gender, duration of HIV disease, serum HDL cholesterol and anthropometry, provides high diagnostic sensitivity and specificity. The dyslipidemias, mainly hypercholesterolemia, hypertriglyceridemia and low-plasma HDL cholesterol, among HIV-infected patients in the pre- and post-HAART eras are summarized. Clinical studies of HADL patients show increased lipolysis, which increases free fatty acid transfer to liver for incorporation into lipoprotein triglycerides that are secreted, and to skeletal muscle where they impair normal insulin signaling. A model of HADL that includes preferential lipolysis in femoral-gluteal fat depots is presented. Relevant therapies include those that inhibit lipolysis (niacin) or increase hepatic fatty acid oxidation (fibrates). Summary: HADL is one of several disorders characterized by dyslipidemia, insulin resistance, and lipodystrophy. The relative acuteness of HADL should facilitate identification of the sequence of metabolic changes that gives rise to the syndrome. Current evidence suggests that deranged energy storage in femoral-gluteal and other peripheral sites is important; the molecular details for the derangement are unknown but are under scrutiny by many investigators.

Original languageEnglish (US)
Pages (from-to)59-67
Number of pages9
JournalCurrent opinion in lipidology
Issue number1
StatePublished - Feb 2004


  • Dyslipidemia
  • HIV
  • Insulin resistance
  • Lipodystrophy
  • Lipolysis
  • Protease inhibitors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Pathophysiology of dyslipidemia and increased cardiovascular risk in HIV lipodystrophy: A model of 'systemic steatosis''. Together they form a unique fingerprint.

Cite this